Semanteon Capital Management LP Makes New $308,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Semanteon Capital Management LP acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,609 shares of the biopharmaceutical company’s stock, valued at approximately $308,000.

Other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in Alnylam Pharmaceuticals by 6.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,431,814 shares of the biopharmaceutical company’s stock valued at $1,139,074,000 after acquiring an additional 364,021 shares during the period. abrdn plc lifted its stake in shares of Alnylam Pharmaceuticals by 910.7% during the 4th quarter. abrdn plc now owns 232,716 shares of the biopharmaceutical company’s stock worth $44,544,000 after buying an additional 209,691 shares during the last quarter. Royal London Asset Management Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals by 86.7% during the 3rd quarter. Royal London Asset Management Ltd. now owns 306,595 shares of the biopharmaceutical company’s stock worth $54,303,000 after buying an additional 142,357 shares during the period. Federated Hermes Inc. acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $26,250,000. Finally, TD Asset Management Inc raised its holdings in Alnylam Pharmaceuticals by 38.0% in the 3rd quarter. TD Asset Management Inc now owns 495,364 shares of the biopharmaceutical company’s stock valued at $87,729,000 after acquiring an additional 136,283 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $143.31 on Friday. The company’s 50 day moving average is $150.29 and its 200-day moving average is $165.97. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the company earned ($1.68) EPS. On average, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ALNY. HC Wainwright reaffirmed a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, March 5th. The Goldman Sachs Group cut Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $230.00 to $173.00 in a research report on Friday, February 16th. Wolfe Research started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. Finally, Wells Fargo & Company dropped their price objective on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research note on Friday, February 16th. Eight equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $215.88.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.